# Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease

> **NCT05986136** · PHASE2,PHASE3 · RECRUITING · sponsor: **Mostafa Bahaa** · enrollment: 50 (estimated)

## Conditions studied

- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** Mesalamine
- **DRUG:** Dapagliflozin 10mg Tab

## Key facts

- **NCT ID:** NCT05986136
- **Lead sponsor:** Mostafa Bahaa
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-20
- **Primary completion:** 2027-08-20
- **Final completion:** 2028-07-20
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05986136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05986136, "Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05986136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*